PLX
Protalix Biotherapeutics Inc
NYSE MKT: PLX · HEALTHCARE · BIOTECHNOLOGY
$2.02
+3.06% today
Updated 2026-05-06
Market cap
$170.81M
P/E ratio
—
P/S ratio
3.24x
EPS (TTM)
$-0.08
Dividend yield
—
52W range
$1 – $3
Volume
0.9M
Protalix Biotherapeutics Inc (PLX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$2.02
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$2.81
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.1B | $0.1B | $0.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -12.50%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.